This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Aceragen Crecimiento futuro

Future controles de criterios 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Aceragen.

Información clave

n/a

Tasa de crecimiento de los beneficios

85.2%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.1%
Tasa de crecimiento de los ingresos	-161.8%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	01 Mar 2023

Actualizaciones recientes sobre el crecimiento futuro

When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?

Jan 31

Recent updates

Idera Pharmaceuticals completes acquisition of Aceragen

Sep 28

We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

Aug 24

We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully

May 11

Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?

Mar 07

When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?

Jan 31

Idera outlines capital requirement to move tilsotolimod toward commercialization in advanced melanoma

Jan 13

Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?

Dec 27

Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

Dec 27

Idera Pharmaceuticals receives $5M in additional proceeds from private placement

Dec 15

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:ACGN - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2024	N/A	-63	N/A	N/A	1
12/31/2023	N/A	N/A	N/A	N/A	1
3/31/2023	7	-41	-30	-30	N/A
12/31/2022	5	-23	-24	-24	N/A
9/30/2022	0	-16	-15	-15	N/A
6/30/2022	N/A	-18	-17	-17	N/A
3/31/2022	N/A	-20	-20	-20	N/A
12/31/2021	N/A	97	-25	-25	N/A
9/30/2021	N/A	24	-28	-28	N/A
6/30/2021	N/A	9	-31	-31	N/A
3/31/2021	N/A	-8	-33	-33	N/A
12/31/2020	N/A	-113	-34	-34	N/A
9/30/2020	N/A	-87	-37	-37	N/A
6/30/2020	N/A	-78	-40	-40	N/A
3/31/2020	1	-65	-42	-42	N/A
12/31/2019	1	-85	-45	-44	N/A
9/30/2019	2	-45	-46	-46	N/A
6/30/2019	2	-46	-47	-47	N/A
3/31/2019	0	-51	-51	-51	N/A
12/31/2018	1	-60	-52	-52	N/A
9/30/2018	1	-63	-52	-52	N/A
6/30/2018	1	-66	-52	-52	N/A
3/31/2018	1	-71	-53	-52	N/A
12/31/2017	1	-66	-55	-55	N/A
9/30/2017	16	-50	-39	-39	N/A
6/30/2017	16	-49	-38	-38	N/A
3/31/2017	16	-41	-33	-33	N/A
12/31/2016	16	-38	N/A	-28	N/A
9/30/2016	1	-51	N/A	-42	N/A
6/30/2016	1	-50	N/A	-43	N/A
3/31/2016	1	-49	N/A	-43	N/A
12/31/2015	0	-49	N/A	-43	N/A
9/30/2015	0	-49	N/A	-44	N/A
6/30/2015	0	-47	N/A	-40	N/A
3/31/2015	0	-42	N/A	-36	N/A
12/31/2014	0	-39	N/A	-31	N/A
9/30/2014	0	-34	N/A	-26	N/A
6/30/2014	0	-29	N/A	-23	N/A
3/31/2014	0	-26	N/A	-21	N/A
12/31/2013	0	-21	N/A	-17	N/A
9/30/2013	0	-21	N/A	-17	N/A
6/30/2013	0	-21	N/A	-17	N/A
3/31/2013	0	-19	N/A	-18	N/A
12/31/2012	0	-22	N/A	-20	N/A
9/30/2012	0	-26	N/A	-19	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Insufficient data to determine if ACGN's forecast earnings growth is above the savings rate (2.2%).

Beneficios vs. Mercado: Insufficient data to determine if ACGN's earnings are forecast to grow faster than the US market

Beneficios de alto crecimiento: Insufficient data to determine if ACGN's earnings are expected to grow significantly over the next 3 years.

Ingresos vs. Mercado: ACGN is forecast to have no revenue next year.

Ingresos de alto crecimiento: ACGN is forecast to have no revenue next year.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Insufficient data to determine if ACGN's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Aceragen Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 88% to US$17.00

Price target increased to US$8.60

When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?

Recent updates

Price target decreased by 88% to US$17.00

Aceragen Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing

Aceragen, Inc. announced delayed 10-Q filing

Aceragen, Inc. Announces John Kirby No Longer Serves as Chief Financial Officer

Aceragen, Inc. Announces Recommendation of Data Monitoring Committee in Terra Study

Aceragen, Inc. Announces Bryant D. Lim to Leave as Senior Vice President, Chief Business Officer and General Counsel of the Company, Effective February 17, 2023

Idera Pharmaceuticals Receives Notification of Non-Compliance from Listing Qualifications Department of Nasdaq

Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA) acquired Aceragen, Inc.

Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA) acquired Aceragen, Inc.

Idera Pharmaceuticals completes acquisition of Aceragen

We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

Insufficient new directors

Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients At Amsterdam UMC

We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully

Insufficient new directors

Idera Pharmaceuticals, Inc., Annual General Meeting, Jun 23, 2022

Idera Pharmaceuticals, Inc. Announces Tilsotolimod Updates

Director Vincent Milano has joined 3rd company board

Director Vincent Milano has joined 3rd company board

Director Vincent Milano has joined 3rd company board

Idera Pharmaceuticals, Inc.(NasdaqCM:IDRA) dropped from Russell Microcap Growth Index

Senior VP & COO recently bought US$60k worth of stock

Independent Chairman recently bought US$101k worth of stock

Senior VP & Chief Medical Officer has left the company

Idera Pharmaceuticals Announces Corporate Updates

Idera Pharmaceuticals, Inc. Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma

Price target increased to US$8.60

Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?

When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?

New 90-day high: US$5.40

Idera outlines capital requirement to move tilsotolimod toward commercialization in advanced melanoma

Idera Pharmaceuticals, Inc. Announces Resignation of R. Clayton Fletcher as Senior Vice President

Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?

Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

President recently sold US$161k worth of stock

President notifies of intention to sell stock

Idera Pharmaceuticals receives $5M in additional proceeds from private placement

We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

New 90-day high: US$3.33

Idera Pharmaceuticals, Inc. Announces Board Changes

Idera Pharma names new operations chief

Earnings beat expectations

Idera Pharmaceuticals EPS misses by $0.37

New 90-day high: US$2.69

New 90-day high: US$2.68

Idera Pharmaceuticals, Inc. announced that it has received $5.1 million in funding

New 90-day high - US$2.22

Idera Pharmaceuticals, Inc.(NasdaqCM:IDRA) dropped from Russell Microcap Value Index

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento